Open Actively Recruiting

Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias

About

Brief Summary

Spinocerebellar ataxias (SCA) are genetic neurological diseases that cause imbalance, poor coordination, and speech difficulties. There are different kinds of SCA and this study will focus on types 1, 2,3, and 6 (SCA 1, SCA 2, SCA 3 , also known as Machado-Joseph disease and SCA 6). The diseases are rare, slowly progressive, cause increasingly severe neurological difficulties and are variable across and within genotypes. The purpose of this research study is to bring together a group of experts in the field of SCA for the purpose of learning more about the disease.

The research questions are: 1. How does your disease progress over time? 2. What are the best ways to measure the progression? 3. Do some genes, other than the gene that is abnormal in your disease, have any effect on the way the disease behaves? This is a nationwide study and we expect that 800 patients will participate all over the USA. The participants will be in the study for an indeterminate period of time. Study visits will be done every 6 or 12 months depending on the participating site.

Study Type
Observational

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
6 Years
Maximum Age
N/A

Inclusion Criteria:

  • Presence of symptomatic ataxic disease
  • Definite molecular diagnosis of SCA 1, 2,3,or 6 either in the subject or another affected family member
  • Willingness to participate in the study and ability to give informed consent.
  • Age 6 years and above

Exclusion Criteria:

  • Known recessive, X-linked and mitochondrial ataxias
  • Exclusion of SCA 1, 2, 3 and 6 by previous DNA testing,
  • A lack of willingness to participate in the study

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
10-001564
Category
Neurology
Urology
Principal Investigator
Contact
Aaron Fisher
Location
  • UCLA Westwood
For Providers
NCT No.
NCT01060371
For detailed technical eligibility, visit ClinicalTrials.gov.